热门资讯> 正文

Apellis Pharmaceuticals报告第四季度业绩

2026-02-24 20:09

Apellis Pharmaceuticals press release (APLS): Q4 net loss of $58.9 million, compared to a net loss of $36.4 million for the same period in 2024.
Revenue of $199.9M (-5.9% Y/Y) beats by $0.46M.
Cash and cash equivalents of $466 million as of December 31, 2025; projected revenues, cash, and cash equivalents expected to be sufficient to fund operations to profitability

More on Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Apellis Pharmaceuticals: A Good Product That Just Misses The Mark
Apellis Pharmaceuticals Q4 2025 Earnings Preview
TTM Technologies, Dutch Bros to join S&P 400 Index; Amneal, Apellis to be part of S&P SmallCap 600

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。